Wuxi apptec launched the DNA coding compound library service package delay to accelerate the early discovery process of new drugs

September 4, 2019 / AP / -- Wuxi apptec today announced the launch of DNA coding compound library service package delay Through the leading DNA coding compound library technology (del for short), it provides more cost-effective and efficient screening services for global customers, so as to speed up the process of new drug discovery, promote the early listing of new drugs and good drugs, and benefit patients around the world The insight service package is a self-service product launched by the Dell platform of Wuxi apptec Through the delay service package, users can obtain a del kit containing more than 8 billion DNA coding small molecule compounds, and self-help complete the target affinity screening experiment according to the user manual, and then return the experimental results to Wuxi apptec After completing the following experiments and analysis such as PCR amplification, quantitative PCR (qPCR quantification), purification and sequencing, Wuxi apptec will feed back a summary report (excluding the structure of small molecular compounds and DNA sequence information) to the user, so that the user can decide whether to carry out the follow-up research according to the report results Compared with the traditional service mode, the operation of delay is simple and efficient, and the cost is significantly reduced In the whole process, users do not need to disclose any target information, and the information transmission is safe and reliable, which can help customers to quickly screen the seedling compounds and greatly shorten the time of early discovery of new drugs "The launch of delay can further enhance the application and development of DNA coding compound technology in the field of new drug research and development, and provide strong technical support for customers to complete early drug discovery faster." Dr Peng Xuanjia, head of the Del team of Wuxi Wuxi Pharmaceutical Co., Ltd., said: "through the cost-effective services, insight will help to reduce the threshold of new drug research and development, so that the majority of innovators and entrepreneurs can benefit from more cutting-edge and efficient new drug research and development technology, so as to accelerate the process of new drug research and development and benefit patients." At present, the platform has 90 billion DNA coding small molecule compounds, most of which are independently designed and customized by the team according to the heat of structure and drug-forming properties, with novel and unique chemical space and structural properties, which can help customers achieve more accurate small molecule compound screening services The platform has successfully screened a number of different kinds of proteins for customers, and found a number of nanomolar level compounds, effectively improving the efficiency of new drug research and development About Wuxi, Wuxi, Wuxi and Wuxi to provide the global biomedical industry with all-round, integrated new drug research and development and production services Through empowering global pharmaceutical, biotechnology and medical device companies, Wuxi apptec is committed to promoting the development process of new drugs and bringing breakthrough diagnosis and treatment programs for patients In line with the tenet of taking research as the first task and taking customers as the center, Wuxi apptec helps customers improve their research and development efficiency through cost-effective and efficient research and development services, covering the research and development and production of chemical drugs, research and development and production of cell and gene therapy, testing of medical devices and other fields At present, the empowering platform of Wuxi apptec is carrying R & D and innovation projects of more than 3600 partners from more than 30 countries around the world, committed to bringing more new drugs and good drugs to patients around the world, and realizing the dream of "no hard drugs and hard diseases in the world" as soon as possible About the platform service of DNA coding compound library of Wuxi apptec Yaomingkant DNA coding compound library platform serves the life science industry, selects target compounds with potential of proprietary drugs from 10 billion DNA coding small molecule compound library by affinity screening method, and is committed to providing global partners with one-stop innovative drug R & D solutions of high efficiency, flexibility and quality involved in del screening technology, from database building to screening Its business is mainly located in China, Europe and North America, with customers ranging from biotechnology companies to large pharmaceutical companies Source: yaomingkant